Business Context and Reporting Period
This Form 8-K Current Report was filed by Vivos Therapeutics, Inc. (NASDAQ: VVOS) on March 1, 2022. The report discloses a material corporate event regarding the departure of a senior executive.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
On March 1, 2022, the Company terminated the employment of Dr. G. Dave Singh, its Chief Medical Officer, "for cause" pursuant to his employment agreement dated October 9, 2020. Dr. Singh is no longer affiliated with the Company effective immediately.
Management Commentary and Outlook
- Operational Impact: Management states that Dr. Singh had been on a sabbatical since September 2021 to serve as an Adjunct Professor at Stanford University.
- Continuity: During his sabbatical, his responsibilities were allocated to other Company personnel and advisors.
- Outlook: The Company does not anticipate that his departure will significantly impact Company operations.
Investor Verification Checklist
- Verify the specific grounds for the "for cause" termination of the Chief Medical Officer.
- Confirm the current status of the Chief Medical Officer role and the identity of the interim or permanent replacement.
- Review the Company's most recent 10-K or 10-Q for financial metrics not included in this 8-K.